VERU News and Press, Veru Inc. From 10/01/22

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

The following slide deck was published by Veru Inc. in conjunction with this event. For further details see: Veru (VERU) Presents At Oncology, Hematology & HemeOnc Conference - Slideshow

MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will participa...

MIAMI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the U.S. Food and Drug Adm...

Veru Inc. ( NASDAQ: VERU ) shares lost ~14% in the morning hours Monday after the FDA postponed an Advisory Committee meeting the agency scheduled early this month to review the company's marketing application for its oral COVID-19 therapy sabizabulin. The FDA has push...

Summary Veru’s business profile is based on a profitable sexual health division plus growth opportunities in oncology and Covid-19 treatment. Its strategy is to use revenue from its legacy business to fund its drug pipeline, which seems sensible over the long term. VERU...

Summary Today, we put Veru Inc. in the spotlight for the first time. The stock fell over 20% trading Wednesday after the FDA stated it would require an AdComm Panel for the company's COVID-19 therapy sabizabulin prior to approval. Was the sell-off an overreaction or a sign of ...

MIAMI, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the U.S. Food and Drug Adm...

VERU ( NASDAQ: VERU ) shares added 11% in pre-market trading Wednesday after the FDA announced an Advisory Committee meeting to review the company’s emergency use authorization (EUA) application for its oral COVID-19 therapy sabizabulin. At the Oct. 06 meeting, ...

MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present a...